Please login to the form below

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

patent rights to their PCSK9 inhibitor cholesterol drugs. ... Amgen filed a patent infringement complaint against Sanofi/Regeneron in 2014, claiming that their Praluent (alirocumab) PCSK9 inhibitor infringed on those patients.

Latest news

Regeneron scores positive data in phase 3 cholesterol trial

Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved
Amgen gets block on sales of Repatha rival in Germany

The lawsuit over the intellectual property for the PCSK9 inhibitor drugs dates back to 2016 when Amgen filed its patent infringement complaint shortly after Repatha was approved for marketing.
Amarin up as FDA speeds Vascepa’s cardiovascular claim review

Other drugs including Amgen's injectable PCSK9 inhibitor Repatha (evolocumab) have achieved a similar level of efficacy in testing but Vascepa’s oral dosing, relatively low cost and absence of side
Sanofi gets cardio outcomes claim for Praluent in EU

The two PCSK9 inhibitors are locked in a battle for the severe, high-risk end of the cholesterol market – mainly patients who are unable to control low-density lipoprotein (LDL) cholesterol ... Complicating the picture is a global intellectual property
Dupixent bounce-back helps stem diabetes declines at Sanofi

Another Regeneron-partnered drug – and another key component for Sanofi’s specialty medicines drive – is cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab), and while sales rose 55% year-on-year to 62m ... At the moment, Sanofi is losing

More from news
Approximately 10 fully matching, plus 42 partially matching documents found.

Latest Intelligence

Pharma deals during November 2014

AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...